SG11201501145SA - NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION - Google Patents

NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION

Info

Publication number
SG11201501145SA
SG11201501145SA SG11201501145SA SG11201501145SA SG11201501145SA SG 11201501145S A SG11201501145S A SG 11201501145SA SG 11201501145S A SG11201501145S A SG 11201501145SA SG 11201501145S A SG11201501145S A SG 11201501145SA SG 11201501145S A SG11201501145S A SG 11201501145SA
Authority
SG
Singapore
Prior art keywords
procnp
biomarker
vascular disorders
pregnancy complication
pregnancy
Prior art date
Application number
SG11201501145SA
Other languages
English (en)
Inventor
Eric Arnold Espiner
Timothy Charles Ramsey Prickett
Original Assignee
Otago Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otago Innovation Ltd filed Critical Otago Innovation Ltd
Publication of SG11201501145SA publication Critical patent/SG11201501145SA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201501145SA 2012-08-13 2013-08-13 NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION SG11201501145SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261682729P 2012-08-13 2012-08-13
PCT/NZ2013/000142 WO2014027899A1 (en) 2012-08-13 2013-08-13 NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION

Publications (1)

Publication Number Publication Date
SG11201501145SA true SG11201501145SA (en) 2015-04-29

Family

ID=50101335

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201501145SA SG11201501145SA (en) 2012-08-13 2013-08-13 NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION
SG10201700872TA SG10201700872TA (en) 2012-08-13 2013-08-13 NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201700872TA SG10201700872TA (en) 2012-08-13 2013-08-13 NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION

Country Status (9)

Country Link
US (1) US10012656B2 (enrdf_load_stackoverflow)
EP (1) EP2883060B1 (enrdf_load_stackoverflow)
JP (1) JP6423788B2 (enrdf_load_stackoverflow)
CN (1) CN104937420B (enrdf_load_stackoverflow)
AU (1) AU2013303302B2 (enrdf_load_stackoverflow)
CA (1) CA2882116A1 (enrdf_load_stackoverflow)
IN (1) IN2015KN00571A (enrdf_load_stackoverflow)
SG (2) SG11201501145SA (enrdf_load_stackoverflow)
WO (1) WO2014027899A1 (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119800A1 (en) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
EP2883060B1 (en) * 2012-08-13 2018-03-21 Otago Innovation Limited NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION
WO2014144231A1 (en) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US20160106821A1 (en) * 2014-10-20 2016-04-21 Massachusetts Institute Of Technology Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
TWI776812B (zh) * 2016-06-02 2022-09-11 荷蘭商菲林公司 血管收縮素-1-受體拮抗劑
WO2018216580A1 (ja) * 2017-05-22 2018-11-29 東ソー株式会社 アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬
US12130294B2 (en) 2018-04-10 2024-10-29 Quanterix Corporation Quantification of biomarkers present in physiological samples

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT407580B (de) * 1999-08-20 2001-04-25 Biomedica Gmbh Indikatorpeptid zur diagnose und/oder vorhersage von cardiovasculären und/oder endothelialen erkrankungen, antikörperzusammensetzung und immunoassay
WO2004099139A1 (en) 2000-09-15 2004-11-18 Baylor University Indole-containing compounds with anti-tubulin and vascular targeting activity
DE602004030342D1 (de) * 2003-06-17 2011-01-13 Otago Innovation Ltd Beurteilung des skelettwachstums unter verwendung von messungen von nt-cnp-peptiden
DE10338733A1 (de) 2003-08-22 2005-03-24 Berdel, Wolfgang E., Prof. Dr.med. Fusionspolypeptide und deren Verwendung für die antivaskuläre Tumortherapie
WO2008042855A2 (en) 2006-09-29 2008-04-10 The Trustees Of The University Of Pennsylvania Use of ultrasound as an antivascular agent
CN103109192A (zh) * 2010-06-18 2013-05-15 塞尚公司 用于妊娠性高血压和先兆子痫的预后和风险评估的标志物
EP2794646A4 (en) 2011-12-23 2015-12-09 Mayo Foundation ASSESSMENT OF STRUCTURAL CHANGES AND RESULTS OF THE KIDNEYS
EP2883060B1 (en) * 2012-08-13 2018-03-21 Otago Innovation Limited NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION

Also Published As

Publication number Publication date
AU2013303302B2 (en) 2017-10-12
AU2013303302A1 (en) 2015-03-12
IN2015KN00571A (enrdf_load_stackoverflow) 2015-07-17
CN104937420B (zh) 2018-07-03
JP6423788B2 (ja) 2018-11-14
US10012656B2 (en) 2018-07-03
US20150241451A1 (en) 2015-08-27
CN104937420A (zh) 2015-09-23
EP2883060A1 (en) 2015-06-17
SG10201700872TA (en) 2017-04-27
CA2882116A1 (en) 2014-02-20
WO2014027899A1 (en) 2014-02-20
EP2883060B1 (en) 2018-03-21
JP2015526725A (ja) 2015-09-10
EP2883060A4 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
IL235826A0 (en) Diazaspirocycloalkane and azaspirocycloalkane
EP2922861A4 (en) BIOMARKER COMPOSITIONS AND METHODS
EP2823306A4 (en) BIOMARKER COMPOSITIONS AND METHODS
GB201423360D0 (en) Adaptive clustering of locations
GB2499463B (en) Reduced sugar syrups and methods of making reduced sugar syrups
SG11201501145SA (en) NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION
HUE042637T2 (hu) Laminátumok és azok elõállítására szolgáló módszerek
ZA201502336B (en) Enzalutamide polymorphic forms and its preparation
GB2500825B8 (en) Alloy and method of production thereof
LT2833884T (lt) Ccr3-inhibitorių panaudojimas
SG11201403731VA (en) Multifunctional structure and method for its manufacture
GB201214362D0 (en) Conical transition piece
PL3901164T3 (pl) Zaburzenia związane z glutenem
GB2502110B (en) Chips and manufacture thereof
IL237862A0 (en) Methods to reduce the formation of scale
PL2903448T3 (pl) Twardy wyrób cukierniczy i sposób jego wytwarzania
GB2503216B (en) Continuity of content
IL239426A0 (en) Methods and compositions of biomarkers
GB2508212B (en) Sanitary product and its method of manufacture
ZA201500353B (en) Method of ameliorating clotting pathologies and related materials and methods
GB201316230D0 (en) Catalysts and methods of making and using catalysts
GB201609028D0 (en) Adaptive clustering of locations
PL2931929T3 (pl) Stop do wytwarzania wyrobów jubilerskich
GB201203142D0 (en) Stents and methods of manufacture
AP00420S1 (en) Anti-mosquitos wristband